摘要
目的:验方参芍宽心合剂已应用于临床,取得满意疗效;实验观察了参芍宽心合剂对心肌梗死模型大鼠血清细胞黏附分子1及E-选择素水平的影响,从动物实验方面探讨其对血管内皮功能的影响。方法:实验于2005-10/2006-06在唐山工人医院中心实验室完成。①实验干预:选用雄性SD大鼠50只,鼠龄10周。采用结扎心脏左前降支的方法建立心肌梗死模型,将40只造模成功的大鼠随机分为4组:模型组,宽心合剂小、大剂量组及治疗对照组,每组10只。取10只大鼠设为假手术组,仅开胸前降支穿线不结扎。于造模后24h模型组、假手术组开始灌胃生理盐水10mL/(kg·d);宽心合剂小、大剂量组:于造模后24h开始灌胃含宽心合剂生药15和30g/(kg·d)混悬液,参芍宽心合剂成分为丹参、黄芪、赤芍等;治疗对照组灌胃消心痛混悬液10mL/(kg·d),连续灌胃4周。②实验评估:采用酶联免疫吸附法测定血清中血管内皮细胞黏附分子1、E-选择素的含量。结果:进入结果分析的大鼠保持为50只。①给药4周后血清内皮细胞黏附分子1水平:假手术组低于其他各组,差异有十分显著性意义(P<0.01);经治疗对照组与小剂量宽心合剂组低于模型组,差异无显著性意义(P>0.05);宽心合剂大剂量组低于模型组,差异有十分显著性意义(P<0.01)。②给药4周后血清E选择素水平:假手术组低于其他各组,差异有十分显著性意义(P<0.01);治疗对照组和宽心合剂组低于模型组,差异有十分显著性意义(P<0.01)。且宽心合剂两个剂量组低于治疗对照组及模型组,差异有十分显著性意义(P<0.01)。宽心合剂大剂量组低于宽心合剂小剂量组,差异有显著性意义(P<0.05)。结论:参芍宽心合剂可以降低心肌梗死模型大鼠血清内皮因子的表达,保护内皮功能,这可能是参芍宽心合剂有效治疗心肌梗死的机制之一。
AIM：Prescription of Danshen Chishao Kuanxin Heji （KXHJ） has been applied in clinic and achieved good curative effect. In this study, the effects of KXHJ on the levels of vascular cell adhesion molecule （VCAM） and E-selectin in rats with acute myocardial infarction, and on endothelial function were explored at experimental animal level.
METHODS： The experiment was performed in the Central Laboratory of Tangshan Workers Hospital from October 2005 to June 2006. ①Fifty 10-week-old male SD rats were selected, and myocardial infarction models were made by ligating the left anterior descending branch. Forty successfully modeled rats were randomly divided into 4 groups （n =10）： model group, low and high dose groups and treatment control group. In addition, another 10 rats were selected as sham operation group, which was not ligated. Twenty-four hours after modeling, the model group and sham operation group were intragastrically infused with normal saline （10 mL/kg daily）; KXHJ groups were infused with 15, and 30 g/kg daily KXHJ suspension （danshen root, astragali, paeoniae radix, and so on）; treatment control group was infused with 10 mL/kg daily Xiaoxintong suspension for 4 weeks. ②The contents of VCAM-1 and E-selectin in serum were measured by ELISA.
RESULTS： Totally 50 rats were involved in the result analysis. ①Four weeks after administration, the level of VCAM-1 in sham operation group was lower than that in each other group significantly （P 〈 0.01）; treatment control group and low dose KXHJ group were lower than model group （P 〉 0.05）; high dose KXHJ group was lower remarkably than model group （P 〈 0.01）.②Four Weeks after administration, the level of E-selectin in sham operation group was lower than that in each other group significantly （P 〈 0.01）; treatment control group and KXHJ groups were markedly lower than model group （P 〈 0.01）; both high and low KXHJ groups were lower remarkably than treatment control group and model group （P 〈 0.01）. The level of E-selectin presented significant difference between high dose group and low dose group （P 〈 0.05）.
CONCLUSION： KXHJ can reduce the expression of serum endothelial factors and protect endothelial function in rats with myocardial infarction, which may be one of the mechanisms to effectively treat myocardial infarction.
出处
《中国组织工程研究与临床康复》
CAS
CSCD
北大核心
2007年第45期9039-9042,共4页
Journal of Clinical Rehabilitative Tissue Engineering Research
基金
国家高新技术发展计划(863计划)(2005AA205232)~~
